CCTX-001: a novel CAR-T therapy for AML

Phase 1 trials of novel CAR T-cells for leukemiaПодробнее

UCARTCS1: a novel allogeneic CAR-T therapy for myelomaПодробнее

Challenges with CAR-T therapy in AML & insights into IF-BETTER-gated CAR-T cellsПодробнее

An insight into CTX130: a novel allogeneic CAR-T cell therapyПодробнее

Dr. Smith Discusses Novel CAR T-Cell Therapies for MyelomaПодробнее

A novel subcutaneous CAR-T therapy for the treatment of hematological malignanciesПодробнее

Challenges in developing CAR-T therapy for AMLПодробнее

Novel ALL treatment strategies: CAR T-cellsПодробнее

Challenges With CAR T-Cell Therapies in AMLПодробнее

Future prospects for CAR-T cell therapy in AMLПодробнее

CAR T-cell therapy for AMLПодробнее

The cost-effectiveness of CAR T-cell therapyПодробнее

CAR T Cell Therapy Explained (Animation) | City of HopeПодробнее

Recent advances in CAR-T therapy for MDSПодробнее

Dr. Park on Challenges With CAR T cells in AMLПодробнее

Novel immunotherapies in AML and insights into the future of the treatment landscapeПодробнее

Gilteritinib and CAR T-cell therapy in high-risk pediatric leukemiasПодробнее

The novel ICAHT grading system to predict toxicity following CAR T-cell therapyПодробнее

CAR T: Jonathan’s StoryПодробнее